LTR Pharma Limited (ASX:LTP) Advances Multi-Market Strategy with FDA Milestone and Roxus Launch
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.
4DMedical Limited (ASX:4DX) announces $6.5m annual cost reductions, supporting ongoing growth and key milestones.
CLINUVEL (ASX:CUV) reports positive preliminary results from its latest stroke treatment study, highlighting high patient improvement rates.
Orthocell Limited (ASX:OCC) achieves first sales of its Striate+ product in the DACH region, marking a significant expansion in its European markets.
EBR Systems (ASX:EBR) reports successful SOLVE-CRT trials and outlines a clear FDA approval pathway for its innovative leadless pacemaker system.
4DMedical Limited (ASX:4DX) completes an oversubscribed $8.4m SPP, raising $13.9m to advance lung diagnostic technologies.
Immutep Limited (ASX:IMM) initiates pivotal Phase III trial for non-small cell lung cancer, aiming to establish new treatment standards.
Telix Pharmaceuticals (ASX:TLX) announces FDA approval for Gozellix®, expanding prostate cancer imaging access in the U.S.
Rhythm Biosciences (ASX:RHY) records its first commercial sales of geneType products, anticipating growth throughout the year.
Imugene Limited (ASX:IMU) secures FDA Fast Track designation for its allogeneic CAR T-cell therapy azer-cel, advancing treatment for relapsed or refractory diffuse large B-cell lymphoma.